Yuchun Zhang

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Alexion Pharmaceuticals, Inc.. Active years: 2015-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuchun Zhang. Retrieved from https://idiyas.com/inventor/yuchun-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 49(Granted Patents)

Location History:

Chesire, CT (US) (2015)
Cheshire, CT (US) (2015 - 2022)

Company Filing History:

9 out of 199

Alexion Pharmaceuticals, Inc.

patents

Years Active: 2015-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11407821 - Anti-C5A antibodies (2022-08-09),

2. 10450370 - Anti-C5a antibodies (2019-10-22),

3. 9963503 - Methods of producing anti-C5a antibodies (2018-05-08),

4. 9469690 - Methods of treating complement-associated disorders with anti-C5a antibodies (2016-10-18),

5. 9434784 - Nucleic acids encodng anti-C5A antibodies (2016-09-06),

6. 9371378 - Anti-C5a antibodies (2016-06-21),

7. 9309310 - Nucleic acids encoding anti-C5a antibodies (2016-04-12),

8. 9221901 - Methods of treating complement-associated disorders with anti-C5a antibodies (2015-12-29),

9. 9011852 - Anti-C5a antibodies (2015-04-21),

Title: Yuchun Zhang - Innovator in Antibody Therapeutics

Introduction

Yuchun Zhang is a prominent inventor based in Cheshire, CT (US), known for his significant contributions to the field of antibody therapeutics. With a total of 9 patents to his name, Zhang has made remarkable strides in developing innovative solutions for various complement-associated disorders.

Latest Patents

Among his latest patents, Zhang has focused on Anti-C5A antibodies. These patents disclose antibodies or antigen-binding fragments that specifically bind to C5a, offering potential treatments for conditions such as atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burns, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Career Highlights

Zhang is currently affiliated with Alexion Pharmaceuticals, Inc., where he continues to advance his research and development efforts in the field of immunology. His work has been instrumental in paving the way for new therapeutic approaches that address critical health challenges.

Collaborations

Throughout his career, Zhang has collaborated with esteemed colleagues, including Russell P Rother and Douglas L Sheridan. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of groundbreaking therapies.

Conclusion

Yuchun Zhang's dedication to innovation in antibody therapeutics positions

Profile summary based on public USPTO records.